TY - JOUR AB - MAP3K1 is a MAPK family serine‑threonine kinase that is frequently mutated in human cancer. The association between mutations in the MAP3K1 gene and the clinicopathological characteristics and prognosis of patients with breast cancer remain unclear in the Chinese population. Thus, the aim of the present retrospective study was to investigate the possible role and function of MAP3K1 in breast cancer. Data obtained from 412 consecutive patients with breast cancer were selected from Guangdong Provincial People's Hospital (GDPH) for analysis in the present study. Mutations were assessed using next‑generation sequencing. The association between MAP3K1 mutations and clinicopathological features were analyzed and further compared with the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort and data from The Cancer Genome Atlas (TCGA). In the GDPH cohort, a total of 45 mutations MAP3K1 were identified in 8.5% (n=35) of the 412 patients, compared with 9.7% (n=244) in METABRIC and 7.9% (n=88) in TCGA. The majority of the mutations identified in the in three cohorts were truncating mutations, followed by mis‑sense mutations. Mutations in MAP3K1 were predominant in patients with the luminal A and B breast cancer subtypes in METABRIC datasets (P<0.001), although no significant differences were observed in the GDPH cohort (P=0.227). In the METABRIC cohort, patients with MAP3K1 mutations experienced a improved overall survival (OS) rate than patients without MAP3K1 mutations (P=0.006). In patient with hormone receptor (HR)+ breast cancer, a more significantly higher OS rate was observed in patients with MAP3K1 mutations (P<0.001). MAP3K1 expression was associated with OS in the HR+ subgroup. Moreover, the MAP3K1 methylation levels were reduced in primary breast cancer tissue, compared with normal tissue. Thus, the present findings identified MAP3K1 mutations in Chinese patients with breast cancer, and compared MAP3K1 mutations between the cohorts from Western and Eastern countries. AD - Department of Breast Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China AU - Li,Cheukfai AU - Zhang,Guochun AU - Wang,Yulei AU - Chen,Bo AU - Li,Kai AU - Cao,Li AU - Ren,Chongyang AU - Wen,Lingzhu AU - Jia,Minghan AU - Mok,Hsiaopei AU - Lai,Jianguo AU - Xiao,Weikai AU - Li,Xuerui AU - Liao,Ning DA - 2022/02/01 DO - 10.3892/ol.2022.13187 IS - 2 JO - Oncol Lett KW - breast cancer MAP3K1 mutation next‑generation sequencing DNA methylation PY - 2022 SN - 1792-1074 1792-1082 SP - 68 ST - Spectrum of MAP3K1 mutations in breast cancer is luminal subtype‑predominant and related to prognosis T2 - Oncology Letters TI - Spectrum of MAP3K1 mutations in breast cancer is luminal subtype‑predominant and related to prognosis UR - https://doi.org/10.3892/ol.2022.13187 VL - 23 ER -